Menarini Group Presents Updated Data Underscoring the Combinability of Elacestrant (ORSERDU®) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2025 Annual Meeting
Preliminary efficacy analysis from the elacestrant plus everolimus and ribociclib cohorts of the ELEVATE study, along with updated safety data from additional cohorts of elacestrant plus targeted therapy combination arms, will be presented.
These data highlight elacestrant's potential role as an endocrine therapy backbone in combination with various targeted agents for patients with ER+/HER2- mBC.
The robust elacestrant clinical development program across wide-ranging studies further solidifies its potential in monotherapy and combination settings, in mBC and in early breast cancer.
FLORENCE, Italy and NEW YORK, May 23, 2025 /CNW/ -- The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, will present updated preliminary efficacy and safety results from the Phase 1b/2 ELEVATE study in patients with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (mBC). The ELEVATE study was designed to evaluate the safety and efficacy of oral-oral combination treatment options to overcome different resistance mechanisms observed in ER+/HER2- mBC and improve patient outcomes. Additionally, various other trial-in-progress updates will be presented, investigating elacestrant's potential to become an endocrine therapy (ET) backbone across the spectrum of breast cancer. These data will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
The ELEVATE study is comprised of six treatment regimens evaluating elacestrant in combination with CDK4/6 inhibitors (palbociclib, abemaciclib and ribociclib) and with inhibitors of the PI3K/AKT/mTOR pathway (everolimus, alpelisib and capivasertib). ELEVATE results reported at ASCO 2025 (abstract 1070/49) include updated efficacy data which demonstrate favorable preliminary progression-free survival (PFS) from the elacestrant plus ribociclib and the elacestrant plus everolimus cohorts. A recommended phase 2 dose (RP2D) was determined to be elacestrant 345 mg plus ribociclib 400 mg. The RP2D of elacestrant 345 mg plus everolimus 7.5 mg was previously reported.
"It is encouraging to see the positive preliminary efficacy and safety results when everolimus and ribocilib, respectively, are combined with elacestrant. These findings are consistent with the promising elacestrant plus abemaciclib cohort data from the same study that was presented last December, which also demonstrated favorable preliminary efficacy and safety in this setting," said Hope S. Rugo, MD, Director, Women's Cancers Program and Division Chief, Breast Medical Oncology, City of Hope Comprehensive Cancer Center. "As the progression-free survival data and safety data continue to mature across the various cohorts of the ELEVATE study, we are encouraged by elacestrant's potential to become an endocrine therapy backbone in combination regimens for the treatment of metastatic breast cancer."
Additional data reported separately (abstract 1079/58) provided updated Phase 1b/2 safety results from four cohorts of the ELEVATE study, including elacestrant plus ribociclib, everolimus, alpelisib, and capivasertib. These updated preliminary results show that the combinations are consistent with the known safety profiles of each targeted therapy plus standard of care endocrine therapy.
"These data continue to underscore the potential value of elacestrant as a combination partner in the ER+/HER2- metastatic breast cancer treatment landscape," said Elcin Barker Ergun, CEO of the Menarini Group. "We are also exploring the potential of elacestrant in other patient populations, including our currently enrolling ELEGANT study, which is designed to assess its potential benefit in early breast cancer patients with high risk of recurrence."
In addition, the company will be presenting other data at the ASCO Annual Meeting. See below for a complete list of Menarini Stemline abstracts.
Menarini Stemline Abstracts:
Presentation Title: Elacestrant (Ela) combinations with ribociclib (Ribo) and everolimus (Eve) in patients (pts) with ER+/HER2- locally advanced or metastatic breast cancer (mBC): Update from ELEVATE, a phase (Ph) 1b/2, open-label, umbrella study.
Abstract Number: 1070
Presentation Date & Time: Monday, June 2, 9:00 AM – 12:00 PM CT
Location: Poster Bd 49
Presenting Author: Hope S. Rugo
Presentation Title: Elacestrant combinations in patients (pts) with ER+/HER2- locally advanced or metastatic breast cancer (mBC): Safety update from ELEVATE, a phase (Ph) 1b/2, open-label, umbrella study.
Abstract Number: 1079
Presentation Date & Time: Monday, June 2, 9:00 AM – 12:00 PM CT
Location: Poster Bd 58
Presenting Author: Nancy Chan
Presentation Title: ADELA: a double-blind, placebo-controlled, randomized phase 3 trial of Elacestrant (ELA) + everolimus (EVE) versus ELA + placebo (PBO) in ER+/HER2- advanced breast cancer (aBC) patients with ESR1-mutated tumors progressing on endocrine therapy (ET) + CDK4/6i.
Abstract Number: TPS1129
Presentation Date & Time: Monday, June 2, 9:00 AM – 12:00 PM CT
Location: Poster Bd 103b
Presenting Author: Antonio Llombart-Cussac
Presentation Title: ELCIN: Elacestrant in women and men with CDK4/6 Inhibitor (CDK4/6i)-naïve estrogen receptor-positive (ER+), HER2-negative (HER2-) metastatic breast cancer (mBC): an open-label multicenter phase 2 study.
Abstract Number: TPS1127
Presentation Date & Time: Monday, June 2, 9:00 AM – 12:00 PM CT
Location: Poster Bd 102b
Presenting Author: Virginia G. Kaklamani
Presentation Title: ELEGANT: Elacestrant versus standard endocrine therapy (ET) in women and men with node-positive, estrogen Receptor-positive (ER+), HER2-negative (HER2-), early breast cancer (eBC) with high risk of recurrence in a global, multicenter, randomized, open-label phase 3 study.
Abstract Number: TPS619
Presentation Date & Time: Monday, June 2, 9:00 AM – 12:00 PM CT
Location: Poster Bd 210a
Presenting Author: Aditya Bardia
Presentation Title: EORTC-2129-BCG: Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA)
Abstract Number: TPS620
Presentation Date & Time: Monday, June 2, 9:00 AM – 12:00 PM CT
Location: Poster Bd 210b
Presenting Author: Michail Ignatiadis
About The Elacestrant Clinical Development Program
Elacestrant is also being investigated in several company-sponsored clinical trials in metastatic breast cancer disease, alone or in combination with other therapies. ELEVATE (NCT05563220) is a phase 1b/2 clinical trial evaluating the safety and efficacy of elacestrant combined with alpelisib, everolimus, capivasertib, palbociclib, ribociclib or abemaciclib. ELECTRA (NCT05386108) is an open-label phase 1b/2, multicenter study evaluating elacestrant in combination with abemaciclib in patients with ER+, HER2- breast cancer. The phase 2 portion evaluates this treatment regimen in patients with brain metastases. ELCIN (NCT05596409) is a phase 2 trial evaluating the efficacy of elacestrant in patients with ER+, HER2- advanced/metastatic breast cancer who received one or two prior hormonal therapies and no prior CDK4/6 inhibitors in the metastatic setting. ADELA (NCT06382948) is a phase 3 randomized, double-blinded trial evaluating elacestrant in combination with everolimus in patients with ER+, HER2- mBC with ESR1-mut tumors. Elacestrant is also being evaluated in additional investigator-led trials, in trials conducted in collaboration with other companies, in metastatic breast cancer as well as in early disease.
About ORSERDU (elacestrant)
U.S. Indication: ORSERDU (elacestrant), 345 mg tablets, is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1 -mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.
Full prescribing information for the U.S. can be found at www.orserdu.com.
Warning and Precautions
Dyslipidemia: Hypercholesterolemia and hypertriglyceridemia occurred in patients taking ORSERDU at an incidence of 30% and 27%, respectively. The incidence of Grade 3 and 4 hypercholesterolemia and hypertriglyceridemia were 0.9% and 2.2%, respectively. Monitor lipid profile prior to starting and periodically while taking ORSERDU.
Embryo-Fetal Toxicity: Based on findings in animals and its mechanism of action, ORSERDU can cause fetal harm when administered to a pregnant woman. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with ORSERDU and for 1 week after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with ORSERDU and for 1 week after the final dose.
Adverse Reactions
Serious adverse reactions occurred in 12% of patients who received ORSERDU. Serious adverse reactions in >1% of patients who received ORSERDU were musculoskeletal pain (1.7%) and nausea (1.3%). Fatal adverse reactions occurred in 1.7% of patients who received ORSERDU, including cardiac arrest, septic shock, diverticulitis, and unknown cause (one patient each). The most common adverse reactions (> 10%), including laboratory abnormalities, of ORSERDU were musculoskeletal pain (41%), nausea (35%), increased cholesterol (30%), increased AST (29%), increased triglycerides (27%), fatigue (26%), decreased hemoglobin (26%), vomiting (19%), increased ALT (17%), decreased sodium (16%), increased creatinine (16%), decreased appetite(15%), diarrhea(13%), headache (12%), constipation (12%), abdominal pain (11%), hot flush (11%), and dyspepsia (10%).
Drug interactions
Concomitant use with CYP3A4 Inducers and/or inhibitors: Avoid concomitant use of strong or moderate CYP3A4 inhibitors with ORSERDU. Avoid concomitant use of strong or moderate CYP3A4 inducers with ORSERDU.
Use in specific populations
Lactation: Advise lactating women to not breastfeed during treatment with ORSERDU and for 1 week after the last dose.
Hepatic Impairment: Avoid use of ORSERDU in patients with severe hepatic impairment (Child-Pugh C). Reduce the dose of ORSERDU in patients with moderate hepatic impairment (Child-Pugh B).
The safety and effectiveness of ORSERDU in pediatric patients have not been established.
To report SUSPECTED ADVERSE REACTIONS, contact Stemline Therapeutics, Inc. at 1-877-332-7961 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
About The Menarini Group
The Menarini Group is a leading international pharmaceutical and diagnostics company, with a turnover of $4.7 billion and over 17,000 employees. Menarini is focused on therapeutic areas with high unmet needs with products for cardiology, oncology, pneumology, gastroenterology, infectious diseases, diabetology, inflammation, and analgesia. With 18 production sites and 9 Research and Development centers, Menarini's products are available in 140 countries worldwide.
For further information, please visit www.menarini.com.
About Stemline Therapeutics Inc.
Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group, is a commercial-stage biopharmaceutical company focused on bringing transformational oncology treatments to patients. Stemline commercializes elacestrant, an oral endocrine therapy indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1 -mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy, in the U.S., Europe, and other global regions. Stemline also commercializes tagraxofusp-erzs, a novel targeted therapy directed to CD123, for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematologic cancer, in the United States, Europe, and other global regions. In addition, Stemline commercializes selinexor, an XPO1 inhibitor for multiple myeloma, in Europe. The company is also conducting multiple label-expansion studies with elacestrant and tagraxofusp in breast and hematologic cancer indications, respectively, and has an extensive clinical pipeline of additional drug candidates in various stages of development for a host of solid and hematologic cancers.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
6 hours ago
- Cision Canada
GLOBAL X ANNOUNCES SEMI-MONTHLY JUNE 2025 DISTRIBUTIONS FOR ITS SUITE OF ETFs Français
TORONTO, June 6, 2025 /CNW/ - Global X Investments Canada Inc. ("Global X") is pleased to announce the distribution amounts per security (the"Distributions") for its exchange traded funds (the " ETFs"), as indicated in the table below. (1) Distributions for Global X Bitcoin Covered Call ETF are declared and paid in Canadian dollars, including those listed under the U.S. dollar traded ticker BCCC.U. The approximate U.S. dollar equivalent distribution rate for BCCC.U is $0.10245 per security. For securityholders who hold the U.S. dollar traded BCCC.U, the securityholder's account holder will typically convert distribution payments to U.S. dollars. (2) Distributions for Global X Enhanced Bitcoin Covered Call ETF are declared and paid in Canadian dollars, including those listed under the U.S. dollar traded ticker BCCL.U. The approximate U.S. dollar equivalent distribution rate for BCCL.U is $0.12805 per security. For securityholders who hold the U.S. dollar traded BCCL.U, the securityholder's account holder will typically convert distribution payments to U.S. dollars. Distributions for the ETFs will vary from period to period. For further information regarding the Distributions, please visit About Global X Investments Canada Inc. ( Global X Investments Canada Inc. is an innovative financial services company and offers one of the largest suites of exchange traded funds in Canada. The Global X Fund family includes a broadly diversified range of solutions for investors of all experience levels to meet their investment objectives in a variety of market conditions. Global X has more than $41 billion of assets under management and 142 ETFs listed on major Canadian stock exchanges. Global X is a wholly-owned subsidiary of the Mirae Asset Financial Group, which manages more than $900 billion of assets across 19 countries and global markets around the world. Commissions, management fees, and expenses all may be associated with an investment in products (the "Global X Funds") managed by Global X Investments Canada Inc. The Global X Funds are not guaranteed, their values change frequently, and past performance may not be repeated. Certain Global X Funds may have exposure to leveraged investment techniques that magnify gains and losses which may result in greater volatility in value and could be subject to aggressive investment risk and price volatility risk. Such risks are described in the prospectus. The Global X Money Market Funds are not covered by the Canada Deposit Insurance Corporation, the Federal Deposit Insurance Corporation, or any other government deposit insurer. There can be no assurances that the money market fund will be able to maintain its net asset value per security at a constant amount or that the full amount of your investment in the Funds will be returned to you. Past performance may not be repeated. The prospectus contains important detailed information about the Global X Funds. Please read the relevant prospectus before investing. The payment of distributions, if any, is not guaranteed and may fluctuate at any time. The payment of distributions should not be confused with an exchange traded fund's ("ETF") performance, rate of return, or yield. If distributions paid by the ETF are greater than the performance of the ETF, distributions paid may include a return of capital and an investor's original investment will decrease. A return of capital is not taxable to the investor but will generally reduce the adjusted cost base of the securities held for tax purposes. Distributions are paid as a result of capital gains realized by an ETF, and income and dividends earned by an ETF are taxable to the investor in the year they are paid. The investor's adjusted cost base will be reduced by the amount of any returns of capital. If the investor's adjusted cost base goes below zero, investors will realize capital gains equal to the amount below zero. Future distribution dates may be amended at any time. To recognize that these distributions have been allocated to investors for tax purposes the amounts of these distributions should be added to the adjusted cost base of the units held. The characterization of distributions, if any, for tax purposes, (such as dividends/other income/capital gains, etc.) will not be known for certain until after the ETF's tax year-end. Therefore, investors will be informed of the tax characterization after year-end and not with each distribution if any. For tax purposes, these amounts will be reported annually by brokers on official tax statements. Please refer to the applicable ETF distribution policy in the prospectus for more information. The Global X Bitcoin Covered Call ETF (BCCC) and the Global X Enhanced Bitcoin Covered Call ETF (BCCL) are each exchange traded alternative mutual funds that invest in other alternative mutual funds that invest, directly or indirectly, in Bitcoin. There are inherent risks associated with products linked to crypto assets, including Bitcoin Futures. While Bitcoin Futures are traded on a regulated exchange and cleared by regulated central counterparties, direct or indirect exposure to the high level of risk of Bitcoin Futures will not be suitable for all types of investors. Given the speculative nature of bitcoin and the volatility of the digital currency markets, there is no assurance that BCCC or BCCL will be able to meet their respective investment objectives. An investment in BCCC or BCCL is not intended as a complete investment program and is appropriate only for investors who have a sophisticated knowledge and understanding of Bitcoin and the capacity to absorb a loss of some or all of their investment. An investment in either BCCC or BCCL is considered high risk. Certain statements may constitute a forward-looking statement, including those identified by the expression "expect" and similar expressions (including grammatical variations thereof). The forward-looking statements are not historical facts but reflect the author's current expectations regarding future results or events. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. These and other factors should be considered carefully, and readers should not place undue reliance on such forward-looking statements. These forward-looking statements are made as of the date hereof and the authors do not undertake to update any forward-looking statement that is contained herein, whether as a result of new information, future events or otherwise, unless required by applicable law. This communication is intended for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to purchase exchange traded products managed by Global X Investments Canada Inc. and is not, and should not be construed as, investment, tax, legal or accounting advice, and should not be relied upon in that regard. Individuals should seek the advice of professionals, as appropriate, regarding any particular investment. Investors should consult their professional advisors prior to implementing any changes to their investment strategies. These investments may not be suitable to the circumstances of an investor. Global X Investments Canada Inc. ("Global X") is a wholly owned subsidiary of Mirae Asset Global Investments Co., Ltd. ("Mirae Asset"), the Korea-based asset management entity of Mirae Asset Financial Group. Global X is a corporation existing under the laws of Canada and is the manager and investment manager of the Global X Funds. © 2025 Global X Investments Canada Inc. All Rights Reserved. SOURCE Global X Investments Canada Inc.
Cision Canada
7 hours ago
- Cision Canada
Edmonton Tourism Awards Honours Outstanding Achievements in the Industry
EDMONTON, AB, June 6, 2025 /CNW/ - The winners of the prestigious Edmonton Tourism Awards 2025 have been announced, recognizing exceptional contributions to the city's tourism scene. Hosted by Edmonton Destination Marketing Hotels (EDMH) and their brand Edmonton's Best Hotels (EBH), these awards celebrate individuals and organizations that have played a pivotal role in promoting Edmonton as a premier travel destination. The third annual ceremony was held Friday, June 6, 2025, at the EXPO Centre to a crowd of over 500. "The Edmonton Tourism Awards is a day of recognition, appreciation, respect, and paying tribute to a job well done. We are delighted to host this celebration and applaud the Best of Edmonton in the tourism industry," said Chris Yeung, Executive Director of Edmonton Destination Marketing Hotels, the hosts of the Edmonton Tourism Awards. The winners of the Edmonton Tourism Awards 2025 are: Attraction of the Year Alberta Legislature and Visitor Centre Business Event of the Year Game Con Canada Culinary Tourism Award Bar OA Farms Culinary Experiences Cultural Experience Award Cariwest Destination Event of the Year Award Canadian Finals Rodeo Fall/Winter Festival of the Year Award (Tie) Edmonton Christmas Market (tied with) Flying Canoe Volant Festival Great Place to Work Tourism Award Delta Hotels by Marriott Edmonton Hotelier, Lifetime Achievement Award Beth Mossop Hotelier, Lifetime Achievement Award Robin Cumine The Peter Ogilvie Tourism Innovator Award and Bursary Kyle Ferguson of the Oilers Entertainment Group Spring/Summer Festival of the Year Award Edmonton International Fringe Theatre Festival Sustainable Tourism Award (Budget under $500K) RiverWatch EcoFloats Sustainable Tourism Award (Budget over $500K) Edmonton Radial Railway Society Sports Event of the Year (Budget over $1 million) 2024 Edmonton Oilers Playoffs Sports Event of the Year (Budget under $1 million) Servus Edmonton Marathon Best Tourism Influencer Award Jen Tomski Special Mentions Art Gallery of Alberta Edmonton Transit Service SOURCE Edmonton Destination Marketing Hotels Ltd.
Cision Canada
7 hours ago
- Cision Canada
Next Edge Capital Corp. Announces Fund Terminations
TORONTO, June 6, 2025 /CNW/ - Next Edge Capital Corp. ("Next Edge"), in its capacity as the Manager of the Next Edge Biotech and Life Sciences Opportunities Fund and Next Edge Strategic Metals and Commodities Fund (collectively the "Funds"), wishes to announce the business decision that it has made to terminate the Funds. As per the sixty (60) day notice period requirement of the Declaration of Trust of the Funds and as per National Instrument 81-102 – Investment Funds, please note that the Funds will terminate effective August 8, 2025 and the notice period will end August 5, 2025 (the " Notice Period"). As of the date of this notice, the Funds have been taken out of distribution and are closed to new investments. Unitholders of the Funds however, may redeem their units on a daily basis at any time at the prevailing Net Asset Value per Unit. If no action is taken by a Unitholder prior to the end of the Notice Period, all Units of the Funds held by that Unitholder will automatically be redeemed as of August 8, 2025 based upon the then prevailing Net Asset Value per Unit. The current prospectus of the Funds is available on the SEDAR+ (System for Electronic Document Analysis and Retrieval) website at or on the Manager's web-site at About Next Edge Capital Corp.: Next Edge is an investment fund manager and a leader in the structuring and distribution of alternative, private credit and value-added fund products in Canada. The firm is led by an experienced management team that has launched numerous investment solutions in a variety of product structures and has been responsible for raising over $3 billion of alternative assets since 2000. 1 Next Edge specializes in and focuses on providing unique, non-correlated pooled investment vehicles to the Canadian marketplace. 1. Please note that over CAD $2 billion of the CAD $3 billion of alternative assets raised relates to assets that were raised at a previous firm(s). Not for release, publication or distribution, in whole or in part, in, into or from any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction.
